JP2017531613A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017531613A5 JP2017531613A5 JP2017500335A JP2017500335A JP2017531613A5 JP 2017531613 A5 JP2017531613 A5 JP 2017531613A5 JP 2017500335 A JP2017500335 A JP 2017500335A JP 2017500335 A JP2017500335 A JP 2017500335A JP 2017531613 A5 JP2017531613 A5 JP 2017531613A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- polypeptide
- subject
- amino acid
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462059682P | 2014-10-03 | 2014-10-03 | |
| US62/059,682 | 2014-10-03 | ||
| PCT/US2015/053700 WO2016054494A1 (en) | 2014-10-03 | 2015-10-02 | Methods and compositions for treatment of conditions associated with elevated triglycerides |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017531613A JP2017531613A (ja) | 2017-10-26 |
| JP2017531613A5 true JP2017531613A5 (enExample) | 2018-11-08 |
| JP6680758B2 JP6680758B2 (ja) | 2020-04-15 |
Family
ID=55631597
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017500335A Expired - Fee Related JP6680758B2 (ja) | 2014-10-03 | 2015-10-02 | 上昇したトリグリセリドと関連する状態の治療のための方法及び組成物 |
Country Status (7)
| Country | Link |
|---|---|
| US (3) | US10071139B2 (enExample) |
| EP (2) | EP3201225B1 (enExample) |
| JP (1) | JP6680758B2 (enExample) |
| AU (1) | AU2015327900B2 (enExample) |
| CA (1) | CA2954082A1 (enExample) |
| ES (1) | ES2819866T3 (enExample) |
| WO (1) | WO2016054494A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3201225B1 (en) | 2014-10-03 | 2020-08-19 | NGM Biopharmaceuticals, Inc. | Angptl8 polypeptide and its use for treatment of conditions associated with elevated triglycerides |
| TW201713690A (zh) * | 2015-08-07 | 2017-04-16 | 再生元醫藥公司 | 抗ａｎｇｐｔｌ８抗體及其用途 |
| SG11201806176PA (en) * | 2016-02-04 | 2018-08-30 | Regeneron Pharma | Non-human animals having an engineered angptl8 gene |
| MA43734A (fr) | 2016-03-03 | 2018-11-28 | Regeneron Pharma | Procédés de traitement de patients atteints d'hyperlipidémie par administration d'un inhibiteur de pcsk9 en combinaison avec un inhibiteur d'angptl3 |
| US20190177391A1 (en) * | 2016-03-31 | 2019-06-13 | Baylor Research Institute | Angiopoietin-like protein 8 (angptl8) |
| RS62769B1 (sr) * | 2016-04-08 | 2022-01-31 | Regeneron Pharma | Postupci za lečenje hiperlipidemije inhibitorom angptl8 i inhibitorom angptl3 |
| EA201991203A1 (ru) | 2016-11-17 | 2019-10-31 | Способы лечения ожирения антителами к angptl8 | |
| AU2018366122A1 (en) | 2017-11-10 | 2020-04-23 | Ngm Biopharmaceuticals, Inc. | ANGPTL8-binding agents and methods of use thereof |
| WO2019126194A1 (en) | 2017-12-18 | 2019-06-27 | Regeneron Pharmaceuticals, Inc. | Angptl8 assay and uses thereof |
| TWI747098B (zh) * | 2018-12-21 | 2021-11-21 | 美商美國禮來大藥廠 | 抗angptl3/8複合物抗體及其使用方法 |
| US12559551B2 (en) | 2019-05-24 | 2026-02-24 | Regeneron Pharmaceuticals, Inc. | Stabilized formulations containing anti-ANGPTL3 antibodies |
| CN110694068A (zh) * | 2019-11-06 | 2020-01-17 | 北京市心肺血管疾病研究所 | 一种抑制血管生成素样蛋白8的物质的应用 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
| US4501728A (en) | 1983-01-06 | 1985-02-26 | Technology Unlimited, Inc. | Masking of liposomes from RES recognition |
| US4837028A (en) | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US20050100991A1 (en) * | 2001-04-12 | 2005-05-12 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| AU2002364586A1 (en) | 2001-12-21 | 2003-07-30 | Delta Biotechnology Limited | Albumin fusion proteins |
| WO2011084714A2 (en) | 2009-12-17 | 2011-07-14 | Biogen Idec Ma Inc. | STABILIZED ANTI-TNF-ALPHA scFv MOLECULES OR ANTI-TWEAK scFv MOLECULES AND USES THEREOF |
| AU2012267492A1 (en) * | 2011-06-10 | 2014-01-09 | President And Fellows Of Harvard College | Modulation of pancreatic beta cell proliferation |
| EP2943512A4 (en) * | 2013-01-11 | 2016-06-01 | California Inst Biomedical Res | BOVINE FUSION ANTIBODY |
| CN105813654B (zh) | 2013-10-11 | 2019-05-31 | 美国政府(由卫生和人类服务部的部长所代表) | Tem8抗体及其用途 |
| EP3201225B1 (en) | 2014-10-03 | 2020-08-19 | NGM Biopharmaceuticals, Inc. | Angptl8 polypeptide and its use for treatment of conditions associated with elevated triglycerides |
| TW201713690A (zh) | 2015-08-07 | 2017-04-16 | 再生元醫藥公司 | 抗ａｎｇｐｔｌ８抗體及其用途 |
| EA201991203A1 (ru) | 2016-11-17 | 2019-10-31 | Способы лечения ожирения антителами к angptl8 | |
| AU2018366122A1 (en) | 2017-11-10 | 2020-04-23 | Ngm Biopharmaceuticals, Inc. | ANGPTL8-binding agents and methods of use thereof |
-
2015
- 2015-10-02 EP EP15848061.6A patent/EP3201225B1/en active Active
- 2015-10-02 US US15/318,937 patent/US10071139B2/en active Active
- 2015-10-02 WO PCT/US2015/053700 patent/WO2016054494A1/en not_active Ceased
- 2015-10-02 EP EP20185093.0A patent/EP3822287A1/en not_active Withdrawn
- 2015-10-02 ES ES15848061T patent/ES2819866T3/es active Active
- 2015-10-02 AU AU2015327900A patent/AU2015327900B2/en not_active Ceased
- 2015-10-02 CA CA2954082A patent/CA2954082A1/en active Pending
- 2015-10-02 JP JP2017500335A patent/JP6680758B2/ja not_active Expired - Fee Related
-
2018
- 2018-08-06 US US16/056,068 patent/US10702587B2/en not_active Expired - Fee Related
-
2020
- 2020-05-29 US US16/888,249 patent/US20210015902A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017531613A5 (enExample) | ||
| JP7365715B2 (ja) | 組織修復のための二重特異性治療用タンパク質 | |
| JP2014526441A5 (enExample) | ||
| Chrysant et al. | Clinical implications of cardiovascular preventing pleiotropic effects of dipeptidyl peptidase-4 inhibitors | |
| JP2019178132A5 (enExample) | ||
| US10702587B2 (en) | Angiopoietin-like protein 8 polypeptide fragments and compositions thereof | |
| JP7834637B2 (ja) | 治療用融合タンパク質 | |
| JP2010513506A5 (enExample) | ||
| JP2012509902A5 (enExample) | ||
| JP2017518303A5 (enExample) | ||
| JP2016512213A5 (enExample) | ||
| CA2971414A1 (en) | Methods of treating tissue calcification | |
| Sarzani et al. | Adipocentric origin of the common cardiometabolic complications of obesity in the young up to the very old: pathophysiology and new therapeutic opportunities | |
| JP2017500316A5 (enExample) | ||
| JP2014519514A5 (enExample) | ||
| JP2007515157A5 (enExample) | ||
| WO2018019840A1 (en) | Pharmaceutical compositions for the treatment of left ventricular hypertrophy and dysfunction associated to metabolic syndrome | |
| JP2017509602A5 (enExample) | ||
| Moreno-Pérez et al. | Are we ready for an adipocentric approach in people living with type 2 diabetes and chronic kidney | |
| Yoo | Infliximab/mesalazine | |
| Wagner et al. | Effect of liraglutide on physical performance in type 2 diabetes (LIPER2): a randomised, double-blind, controlled trial | |
| JP2018500386A5 (enExample) |